JP2024529009A5 - - Google Patents

Info

Publication number
JP2024529009A5
JP2024529009A5 JP2024506806A JP2024506806A JP2024529009A5 JP 2024529009 A5 JP2024529009 A5 JP 2024529009A5 JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024529009 A5 JP2024529009 A5 JP 2024529009A5
Authority
JP
Japan
Prior art keywords
sustained
dosage form
pharmaceutical dosage
injectable pharmaceutical
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/056229 external-priority patent/WO2023281406A1/en
Publication of JP2024529009A publication Critical patent/JP2024529009A/ja
Publication of JP2024529009A5 publication Critical patent/JP2024529009A5/ja
Pending legal-status Critical Current

Links

JP2024506806A 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療 Pending JP2024529009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (2)

Publication Number Publication Date
JP2024529009A JP2024529009A (ja) 2024-08-01
JP2024529009A5 true JP2024529009A5 (cg-RX-API-DMAC7.html) 2025-06-19

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506806A Pending JP2024529009A (ja) 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療

Country Status (8)

Country Link
US (1) US20240277654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4366726A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529009A (cg-RX-API-DMAC7.html)
KR (1) KR20240117521A (cg-RX-API-DMAC7.html)
CN (1) CN118284414A (cg-RX-API-DMAC7.html)
AU (1) AU2022308198A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227324A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023281406A1 (cg-RX-API-DMAC7.html)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE410186T1 (de) 2003-06-26 2008-10-15 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
EP2054073B1 (en) 2006-07-11 2014-11-26 Foresee Pharmaceuticals, Inc. Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
WO2010040188A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
WO2013063125A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
JP6282231B2 (ja) 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドAllergan,Incorporated 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
PT3010962T (pt) 2013-06-20 2017-09-05 Pharmathen Sa Preparação de micropartículas polilactida-poliglicolida com um perfil de libertação sigmoide
FR3034019B1 (fr) * 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
KR101900482B1 (ko) * 2017-01-17 2018-09-19 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법

Similar Documents

Publication Publication Date Title
JP2016528302A5 (cg-RX-API-DMAC7.html)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
JP2014198723A5 (cg-RX-API-DMAC7.html)
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP2016506933A5 (cg-RX-API-DMAC7.html)
JP2021511365A5 (cg-RX-API-DMAC7.html)
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP2020193206A5 (cg-RX-API-DMAC7.html)
US20040192765A1 (en) Use of enantiomeric pure escitalopram
JPS61200911A (ja) 鎮痛剤組成物
CN104013638B (zh) 当药黄素及其衍生物的用途
CN103239439B (zh) 用于治疗高血脂及动脉粥样硬化的组合物及其用途
JP2024528731A5 (cg-RX-API-DMAC7.html)
JP2019085364A5 (cg-RX-API-DMAC7.html)
Khawaja et al. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2013032308A5 (cg-RX-API-DMAC7.html)
JP2023521634A5 (cg-RX-API-DMAC7.html)
JP2024543259A5 (cg-RX-API-DMAC7.html)
Davis Mirtazapine and depressions
JP2023518430A5 (cg-RX-API-DMAC7.html)
JP2007513095A5 (cg-RX-API-DMAC7.html)
MX2009001219A (es) Composicion farmaceutica que contiene en combinacion saredutant y un inhibidor selectivo de recaptacion de serotonina o un inhibidor de recaptacion de serotonina/norepinefrina.
CN101152201A (zh) 异槲皮苷在制备预防和/或治疗抑郁症药物中的应用